Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Lipoidosis
Interventions: SCH-58235; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcohol Use Disorder, Smoking
Interventions: Oxytocin nasal spray, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cleft Palate, Cleft Lip and Palate
Interventions: Book-Sharing for Toddlers with Clefts (BOOST); Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 20 Months to 32 Months
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type2Diabetes, Diabetes
Interventions: QBSafe; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Kidney Cancer, Renal Cancer, Renal Neoplasm
Interventions: Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 99 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain
Interventions: Lidocaine, Sterile Saline; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Pneumonia
Interventions: CP-70,429 and PF-03709270; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Behcet Disease
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Arlington, Texas • Houston, Texas

Conditions: Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions: Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure; Procedure · Genetic · Other
Lead sponsor: National Tuberous Sclerosis Association; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2050
U.S. locations: 24
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 19 more

Conditions: Spinal Stenosis Occipito-Atlanto-Axial, Spinal Disease, Spinal Stenosis Cervical, Spinal Stenosis Cervicothoracic Region, Spinal Instability
Interventions: Streamline Occipito-Cervico-Thoracic Spinal Fixation System; Device
Lead sponsor: RTI Surgical; Industry
Eligibility: Not listed
Enrollment: 60 participants
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Las Vegas, Nevada • Reno, Nevada

Conditions: Bipolar Disorder, Bipolar and Related Disorders, Veterans, Suicide, Suicidal Ideation, Mental Disorders
Interventions: Soterix 1x1 tES mini-CT; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Congestive Heart Failure
Interventions: self-paced instruction; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 95 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Facial Wrinkles, Jawline Contour, Skin Laxity
Interventions: SofWave; Device
Lead sponsor: Sofwave Medical LTD; Industry
Eligibility: 40 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia, Depression, Suicidal Ideation
Interventions: Zolpidem-CR, Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 4
States / cities: Augusta, Georgia • Durham, North Carolina • Wake Forest, North Carolina + 1 more

Conditions: Atrial Fibrillation Paroxysmal
Interventions: Riluzole 50 MG; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: AML and High Risk MDS
Interventions: LGH447, LGH447 + midostaurin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lymphangioleiomyomatosis
Interventions: Letrozole, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 9
States / cities: Stanford, California • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 2,122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 13
States / cities: Chula Vista, California • Spring Valley, California • Walnut Creek, California + 10 more

Conditions: Osteoporosis
Interventions: Not listed
Lead sponsor: Artann Laboratories; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urinary Incontinence
Interventions: Patient Education, Nurse Navigation, ChatBot; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Overweight, Obesity, Weight Management, Appetite Control
Interventions: MN Nutra GeLiPthin-1™ Dietary Supplement, Placebo; Dietary Supplement
Lead sponsor: MNnutra; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Anaemia
Interventions: GSK1278863, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 46
States / cities: Azusa, California • Bakersfield, California • Chino, California + 38 more

Search by objective public record fields.

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

Alcohol and Cigarette Craving During Oxytocin Treatment

Book Sharing for Toddlers With Clefts

QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes.

NSAID Use After Robotic Partial Nephrectomy

Intrauterine Lidocaine Infusion for Essure Sterilization Procedures

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

Phase III Study in Refractory Behcet's Disease

TSC Biosample Repository and Natural History Database

Streamline Occipito-Cervico-Thoracic System Post-Market Clinical Follow-up

Targeted Alternating Current and Cognitive Training Intervention for Cognitive Control in Bipolar Disorders

Developing and Assessing Competencies for Caregivers and Patients With Ventricular Assist Devices

Evaluation of SofWave Sofware-Guided Energy Delivery for Lower Face and Neck Rejuvenation

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Reducing Suicidal Ideation Through Insomnia Treatment

RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Letrozole for Lymphangioleiomyomatosis

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Bone UltraSonic Scanner (BUSS) Clinical Optimization Study

Improving Care for Women With Urinary Incontinence (EMPOWER)

A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis